m+Medelevator.RU
← Поиск публикаций
International journal of pharmaceutics · 2026

Development of dissolving microneedles using a quality by design approach for transdermal delivery of the nanoemulsified volatile compound β-caryophyllene.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Weimer Patrícia, Bordignon Isabella Morel, Mineto Alexandre Rolim, de Oliveira Araujo Karen, Waszak Júlia Cordeiro, Brazil Nathalya Tesch, Collares Fabrício Mezzomo, Dul Maria, Rossi Rochele Cassanta, Koester Letícia Scherer

Аннотация

This study examines transdermal delivery of a β-caryophyllene (a lipophilic and volatile compound) loaded nanoemulsion from dissolving water-soluble polymer microneedles (microneedle array patches - MAPs). Development of this system was guided by the principles of Quality by Design; after defining a quality target product profile and critical quality attributes, a rational experimental plan optimized a formulation to maximize the β-caryophyllene content in MAPs. The optimized formulation consists of polyvinyl pyrrolidone combined with polyvinyl alcohol (combination ratio of 1.54) and a β-caryophyllene-to-polymer mass ratio of 0.09. The β-caryophyllene content was maintained higher than 95 % in relation to the additional mass following the micromolding process and after 45 days of storage. In vitro skin insertion, dissolution, mechanical properties, and transdermal delivery have been investigated for the prototype. A key feature of this work is demonstrating the feasibility of delivering a volatile compound through MAP by associating it with a nanoemulsion. This combined delivery method allows for the transdermal administration of β-caryophyllene, which cannot be achieved through topical nanoemulsion application alone. Overall, the developed system offers a promising alternative to traditional topical and oral pharmaceutical dosage forms.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты